Evox Therapeutics has acquired Codiak Biosciences’ engEx-AAV™ technology platform, gaining the intellectual property rights and exclusive access to associated engineering and manufacturing rights. The technology allows for the loading of adeno-associated virus (AAV) into exosomes, enhancing AAV delivery, expanding expression in pre-clinical models, and protecting AAVs from neutralizing antibodies. The acquisition strengthens Evox’s intellectual property portfolio and supports their strategy of using exosome-mediated delivery for the development of genetic medicines like gene therapy and genome editors.
Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, has purchased Codiak Biosciences engEx-AAV™ technology platform, including all intellectual property rights therein, as well as secured exclusive access to certain engineering and manufacturing rights associated with it. This technology enables active loading of adeno-associated virus (AAV) into exosomes followed by their release when the AAV-loaded exosomes are delivered into recipient cells. This has been demonstrated to be an effective way to improve AAV delivery, to increase the breadth of expression in pre-clinical models, and to shield AAVs from neutralizing antibodies.
“We are pleased to now own this technology and look forward to applying it in future exosome AAV programs. This acquisition further adds to our dominant intellectual property portfolio of patents that cover key aspects needed to develop and commercialise exosome therapeutics including their design, composition, and manufacture,” said Per Lundin, Ph.D., Chief Business Officer & Co-Founder of Evox Therapeutics. “This is part of our long-term business strategy of leveraging improved exosome-mediated delivery to create and enable genetic medicines such as gene therapy and genome editors”.
Source: BioSpace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.